Recent News

• 03.30.2026 - Unicycive Therapeutics Announces Full Year 2025 Financial Results and Provides Business Update
• 02.04.2026 - Unicycive Therapeutics to Participate in a Fireside Chat at Guggenheim’s Emerging Outlook: Biotech Summit
• 01.29.2026 - Unicycive Therapeutics Announces FDA Acceptance of Oxylanthanum Carbonate (OLC) New Drug Application (NDA) Resubmission
• 12.29.2025 - Unicycive Therapeutics Announces Resubmission of New Drug Application (NDA) for Oxylanthanum Carbonate (OLC)
• 11.25.2025 - Unicycive Therapeutics to Participate in Upcoming Investor Events in December
• 11.12.2025 - Unicycive Therapeutics Announces Third Quarter 2025 Financial Results and Provides Business Update

Recent Filings

• 02.17.2026 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 02.13.2026 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 02.10.2026 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 01.23.2026 - SCHEDULE 13G Statement of Beneficial Ownership by Certain Investors
• 11.14.2025 - 8-K Current report
• 11.14.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 11.14.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 11.14.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 11.14.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 11.14.2025 - 424B5 Prospectus [Rule 424(b)(5)]